The frequency of PD-L1 expression (TPS > 1%) in solid tumors varies in different tumors, i.e., non-small cell lung cancer (59.7%), endocrine tumors (47.1%), head and neck tumors (25.9%), and neuroendocrine tumors (15.4%)31. This evidence concerns the gene CD274 and neuroendocrine neoplasm.